Project Grant HT9425261E288
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $1.3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92122, USA
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Institute For Cancer Research a $1,959,353 project grant effective September 1, 2025 through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). This award supports clinical research investigating pembrolizumab maintenance therapy following enfortumab vedotin/pembrolizumab induction treatment in front-line metastatic urothelial carcinoma. The research will be conducted at the...
- Federal Project Grant Award Summary Panorama Research Incorporated received a $405,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 1, 2025 through May 31, 2027. The award supports research targeting dual cancer-specific antigens using novel immunotherapies with a safe and controlled immune booster for the treatment of advanced ovarian cancer. The project will be performed at the company's...
- Federal Project Grant Award Summary Health Research, Inc. (Roswell Park Division) received a $1.15M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2029. The award supports research focused on leveraging infiltrating myeloid cells to improve therapeutic response to bispecific T cell-engaging (BiTE) secreting T cells in ovarian cancer treatment. This research initiative represents...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Beckman Research Institute of the City of Hope a $1.1M project grant effective June 1, 2026 through May 31, 2029 under the Military Medical Research and Development program (CFDA 12.420) to develop LRRC15-targeted Chimeric Antigen Receptor (CAR) T cell therapy for osteosarcoma treatment. This research initiative represents the DHA's investment in innovative cancer immunotherapy solutions with potential military and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, San Diego a $1.65 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026, through April 30, 2029. The research initiative, titled "Targeting Oncoembryonic Antigens to Overcome Therapy Resistance in Patients with Triple-Negative Breast Cancer," focuses on developing innovative therapeutic approaches to address treatment-resistant...
- Federal Grant Award Summary Beckman Research Institute of the City of Hope received a $2.136 million Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2028. The award supports developmental therapeutics research and the investigation of potential treatment strategies targeting RALBP1 (Retinoid-binding Protein 1) for castration-resistant prostate carcinoma. This...
- Federal Grant Award Summary Award Details: The Sloan-Kettering Institute for Cancer Research received a $1.39M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with performance extending through August 31, 2029. The award supports an integrated immunomodulatory analysis of LAG3 (Lymphocyte-Activation Gene 3) inhibition in renal cell carcinoma (RCC), a hypothesis-driven research initiative addressing...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...